<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04004819</url>
  </required_header>
  <id_info>
    <org_study_id>MRCTA,ECFAHOFFMU[2019]142</org_study_id>
    <nct_id>NCT04004819</nct_id>
  </id_info>
  <brief_title>Rituximab for Multiple System Atrphy</brief_title>
  <official_title>Rituximab Therapy for the Patients With Multiple Syetem Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroprotective or anti-inflammatory strategies are invaluable in multiple system atrophy
      (MSA) due to its rapid progression with fatal prognosis. We evaluated the efficacy of
      rituximab in patients with MSA-cerebellar type (MSA-C).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 15, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Experimental: Rituximab group Drug: Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused
Placebo Comparator: Control group Patients will receive usual care and drug use.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of change from baseline to 12 months in total UMSARS I score</measure>
    <time_frame>up to 360 days</time_frame>
    <description>TUMSARS, Unified Multiple System Atrophy Rating Scale,a functional score of symptoms and ability to undertake activities of daily living usually consisting of 12 questions (we omitted question 11 [sexual function] because the question was poorly designed for women). Each question was scored from 0 to 4, with a higher score indicating a lower functional status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in immunology function</measure>
    <time_frame>up to 360 days</time_frame>
    <description>Use the flow cytometry to measure the change at baseline, 90,180, 360 days after drug use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Rituximab group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab will be administered as 100 mg IV, once per week for 3 consecutive weeks. Continued dosage was dependent on the percentage of circulating CD19 B-cell counts from patients . Whenever it reached 1% of total lymphocyte population, rituximab 100 mg was reinfused</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive usual care and drug use.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>A lower dosage of rituximab for multiple system atrophy</description>
    <arm_group_label>Rituximab group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Patients with probable MSA-C or it's mimic (tropical spastic paraparesis)

          -  Baseline unified MSA rating scale scores of 30 to 50

          -  MMSE&gt; 24

          -  Disease duration &lt; 5 years

        Exclusion Criteria:

          -  Anticipated survival of at least 3 years

          -  Inability to undergo neuroimaging with Magnetic Resonance

          -  Clinically significant hepatic disease as demonstrated by history, clinical exam
             (ascites, varices), or laboratory findings (LFTs &gt;2x normal, coagulopathy as
             described)

          -  Comorbid conditions likely to complicate therapy including but not limited to the
             following: a history of New York Heart Association class II, III, or IV Congestive
             Heart Failure; end-stage acquired immune deficiency syndrome

          -  Pregnancy

          -  Malignancy (history of or active)

          -  Concomitant use with antineoplastic, immunosuppressive or immune modulating therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Neurology ,First Affiliated Hospital Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Fu, MD, PhD</last_name>
      <phone>13920263588</phone>
      <email>fuying1995@163.com</email>
    </contact>
    <investigator>
      <last_name>Wan-Jian Chen, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2019</study_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital of Fujian Medical University</investigator_affiliation>
    <investigator_full_name>Wan-Jin Chen</investigator_full_name>
    <investigator_title>Neurology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

